Axsome Therapeutics enters the post-earnings week with a curious split: the Street is raising price targets while short sellers are quietly rebuilding positions, creating a tug-of-war around a stock that has already given back 8% over the past month.
The most notable move this week came from the analyst community. Five firms raised their price targets in a single day following the August 10 earnings print, with the direction of travel unmistakably bullish — Mizuho moved to $316, RBC held its Outperform despite a small trim to $297, and Guggenheim, Wells Fargo, and Needham all nudged higher. Morgan Stanley, the one note of caution, kept its Equal-Weight but still lifted its target to $251. The consensus mean lands near $285, roughly 32% above the current price of $215.77. That gap is wide enough to be meaningful rather than mechanical. Bulls point to accelerating Auvelity and Sunosi sales, a recent FDA approval for Alzheimer's agitation, and a pipeline extending into cataplexy, binge-eating disorder, and schizophrenia. The bear case is more nuanced than outright skepticism — it reads closer to execution risk on a company still scaling its commercial infrastructure.
Positioning tells a more cautious story than the analyst tone suggests. Short interest jumped 11% in a single session on August 11, pushing to 6.7% of the free float — the highest level in roughly six weeks and up meaningfully from the 5% range that dominated mid-July. The rebuild is notable because it follows a period of relative calm: SI had drifted sideways near 3 million shares through most of July before spiking sharply in the final two sessions of the reporting week. That pattern looks less like a slow-building structural short and more like a tactical response to the post-earnings price action, where the stock rose only 1.4% on results day before falling 2.3% the following session. The borrow market does not reinforce the bearish thesis, however — cost to borrow is just 0.43%, near its lowest level in months, and availability is extraordinarily loose at over 6,600% of short interest. There is effectively no friction for new shorts, but equally no squeeze risk for those already short.
Options positioning is neutral to mildly constructive. The put/call ratio of 0.83 is nearly flat to its 20-day average of 0.82, with a z-score barely above zero. There is no sign of elevated hedging demand or directional conviction from the options market — a contrast to how the stock traded heading into the prior quarter, when the PCR had reached higher levels. The ORTEX short score has ticked up to 45.7 from 42.9 two weeks ago, a mild escalation that reflects the SI rebuild but falls well short of anything that would flag serious short pressure.
Factor positioning adds context to the bull case. EPS momentum ranks in the 97th and 98th percentile on both 30-day and 90-day windows — among the strongest in the universe. Forward earnings estimates are rising sharply, with the 12-month forward EPS year-on-year increase scoring in the 88th percentile. The analyst recommendation differential scores at the 93rd percentile, meaning the Street's positive skew relative to peers is unusually pronounced. Against that backdrop, the valuation is genuinely stretched: PE near 92x and EV/EBITDA around 189x leave limited room for execution stumbles. Price-to-book has eased slightly over the past month, down from even more elevated levels, but remains above 60x.
Insider activity adds a layer worth noting. CEO Herriot Tabuteau sold just under $10.5 million worth of stock across two transactions in early August, following an $11.9 million sale in July and a similar-sized June sale by Tabuteau alongside a $7.9 million CFO sale. The cadence is consistent enough that it reads as a structured selling program rather than a directional signal, but the aggregate net insider sales over the past 90 days exceed $46 million — a figure that positions-focused investors will clock against the analyst optimism.
The next test for AXSM is whether the post-earnings target upgrades translate into renewed institutional buying or whether the short rebuild and insider selling cadence continue to cap recovery attempts from the month-long pullback.
See the live data behind this article on ORTEX.
Open AXSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
